Baidu
map

J Investig Clin Dent:牙科麻醉中可乐定对利多卡因局麻的影响

2017-11-15 李伟超 “罂粟花”微信号

局麻中利多卡因可以混合肾上腺素,肾上腺素可被可乐定所替代,此种替代在各种随机对照试验中进行了试验。因此,当前此系统评价的目的是收集利多卡因加可乐定行牙科麻醉的证据。

背景与目的:局麻中利多卡因可以混合肾上腺素,肾上腺素可被可乐定所替代,此种替代在各种随机对照试验中进行了试验。因此,当前此系统评价的目的是收集利多卡因加可乐定行牙科麻醉的证据。

方  法:搜寻了电子数据库进行适当的研究。创建新的数据提取形式,使用RevMan 5.3软件中的非Cochrane模式分析提取数据。使用森林图,I2统计量(其中> 50%被认为具有中度至重度差异性)和χ2检验来评估研究之间的差异。中等差异性使用随机效应模型。最后回顾包括了五项研究。

结  果:发现可乐定在主观测量时明显缩短了局部麻醉的起效时间,客观上没有观察到显着性差异。在持续时间和术后镇痛方面没有观察到明显差异。术后观察到在使用可乐定时血流动力学参数稳定。

结  论:有肾上腺素使用禁忌症的情况下,如心脏异常,高血压糖尿病,可乐定可替代肾上腺素。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2050929, encodeId=798020509290d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 26 18:12:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663856, encodeId=bfe1166385649, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Tue May 15 13:12:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683410, encodeId=d9a11683410d5, content=<a href='/topic/show?id=a27838412cd' target=_blank style='color:#2F92EE;'>#可乐定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38412, encryptionId=a27838412cd, topicName=可乐定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217127964539, createdName=vera_1212, createdTime=Tue Aug 14 11:12:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288836, encodeId=fded128883656, content=<a href='/topic/show?id=0b1e322e85e' target=_blank style='color:#2F92EE;'>#利多卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32278, encryptionId=0b1e322e85e, topicName=利多卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461321, encodeId=50cb146132106, content=<a href='/topic/show?id=67356e62003' target=_blank style='color:#2F92EE;'>#牙科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67620, encryptionId=67356e62003, topicName=牙科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d786418402, createdName=xzw115, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569582, encodeId=efdc156958263, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2050929, encodeId=798020509290d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 26 18:12:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663856, encodeId=bfe1166385649, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Tue May 15 13:12:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683410, encodeId=d9a11683410d5, content=<a href='/topic/show?id=a27838412cd' target=_blank style='color:#2F92EE;'>#可乐定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38412, encryptionId=a27838412cd, topicName=可乐定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217127964539, createdName=vera_1212, createdTime=Tue Aug 14 11:12:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288836, encodeId=fded128883656, content=<a href='/topic/show?id=0b1e322e85e' target=_blank style='color:#2F92EE;'>#利多卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32278, encryptionId=0b1e322e85e, topicName=利多卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461321, encodeId=50cb146132106, content=<a href='/topic/show?id=67356e62003' target=_blank style='color:#2F92EE;'>#牙科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67620, encryptionId=67356e62003, topicName=牙科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d786418402, createdName=xzw115, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569582, encodeId=efdc156958263, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2050929, encodeId=798020509290d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 26 18:12:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663856, encodeId=bfe1166385649, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Tue May 15 13:12:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683410, encodeId=d9a11683410d5, content=<a href='/topic/show?id=a27838412cd' target=_blank style='color:#2F92EE;'>#可乐定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38412, encryptionId=a27838412cd, topicName=可乐定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217127964539, createdName=vera_1212, createdTime=Tue Aug 14 11:12:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288836, encodeId=fded128883656, content=<a href='/topic/show?id=0b1e322e85e' target=_blank style='color:#2F92EE;'>#利多卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32278, encryptionId=0b1e322e85e, topicName=利多卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461321, encodeId=50cb146132106, content=<a href='/topic/show?id=67356e62003' target=_blank style='color:#2F92EE;'>#牙科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67620, encryptionId=67356e62003, topicName=牙科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d786418402, createdName=xzw115, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569582, encodeId=efdc156958263, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2050929, encodeId=798020509290d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 26 18:12:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663856, encodeId=bfe1166385649, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Tue May 15 13:12:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683410, encodeId=d9a11683410d5, content=<a href='/topic/show?id=a27838412cd' target=_blank style='color:#2F92EE;'>#可乐定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38412, encryptionId=a27838412cd, topicName=可乐定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217127964539, createdName=vera_1212, createdTime=Tue Aug 14 11:12:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288836, encodeId=fded128883656, content=<a href='/topic/show?id=0b1e322e85e' target=_blank style='color:#2F92EE;'>#利多卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32278, encryptionId=0b1e322e85e, topicName=利多卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461321, encodeId=50cb146132106, content=<a href='/topic/show?id=67356e62003' target=_blank style='color:#2F92EE;'>#牙科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67620, encryptionId=67356e62003, topicName=牙科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d786418402, createdName=xzw115, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569582, encodeId=efdc156958263, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2050929, encodeId=798020509290d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 26 18:12:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663856, encodeId=bfe1166385649, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Tue May 15 13:12:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683410, encodeId=d9a11683410d5, content=<a href='/topic/show?id=a27838412cd' target=_blank style='color:#2F92EE;'>#可乐定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38412, encryptionId=a27838412cd, topicName=可乐定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217127964539, createdName=vera_1212, createdTime=Tue Aug 14 11:12:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288836, encodeId=fded128883656, content=<a href='/topic/show?id=0b1e322e85e' target=_blank style='color:#2F92EE;'>#利多卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32278, encryptionId=0b1e322e85e, topicName=利多卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461321, encodeId=50cb146132106, content=<a href='/topic/show?id=67356e62003' target=_blank style='color:#2F92EE;'>#牙科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67620, encryptionId=67356e62003, topicName=牙科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d786418402, createdName=xzw115, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569582, encodeId=efdc156958263, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2017-11-17 xzw115
  6. [GetPortalCommentsPageByObjectIdResponse(id=2050929, encodeId=798020509290d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 26 18:12:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663856, encodeId=bfe1166385649, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Tue May 15 13:12:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683410, encodeId=d9a11683410d5, content=<a href='/topic/show?id=a27838412cd' target=_blank style='color:#2F92EE;'>#可乐定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38412, encryptionId=a27838412cd, topicName=可乐定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217127964539, createdName=vera_1212, createdTime=Tue Aug 14 11:12:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288836, encodeId=fded128883656, content=<a href='/topic/show?id=0b1e322e85e' target=_blank style='color:#2F92EE;'>#利多卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32278, encryptionId=0b1e322e85e, topicName=利多卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461321, encodeId=50cb146132106, content=<a href='/topic/show?id=67356e62003' target=_blank style='color:#2F92EE;'>#牙科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67620, encryptionId=67356e62003, topicName=牙科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d786418402, createdName=xzw115, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569582, encodeId=efdc156958263, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Fri Nov 17 02:12:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2017-11-17 by2014

相关资讯

Indian J Anaesth:全麻中应用可乐定可有效实现控制性降压

平衡麻醉时控制性降压可减少失血。本研究旨在评估功能性内镜鼻窦手术(FESS)中静脉注射可乐定来建立控制性低血压的效果。 采用随机、双盲、安慰剂对照研究设计,在印度的一所三级医院进行。纳入60名接受FESS的美国麻醉医师学会身体状况I、II期的患者(18–65年)进行研究,并随机分组——安慰剂组(A组,n = 30)接受无菌水,而可乐定组(B组,n = 30)在麻醉诱导前30分钟静脉注射可乐定

Lancet Child Adol Health:可乐定预防儿童七氟醚麻醉后的术后躁动

研究认为,可乐定可安全地用于预防男孩七氟醚麻醉后的术后躁动

NEJM:非心脏手术患者围术期用阿司匹林或可乐定不改善预后(POISE-2研究)

2014年美国心脏病学会年会(ACC 2014)公布的POISE-2研究表明,在接受非心脏手术的患者中,围术期应用阿司匹林或可乐定(clonidine)均不能减少患者死亡或心肌梗死发生率,应用阿司匹林还与额外严重出血显著相关,可乐定则与额外临床低血压、心动过缓和非致命性心搏骤停显著相关。大出血和低血压是术后心肌梗死的预测因子。研究3月31日在线发表于《新英格兰医学杂志。 研究纳入接受非心脏手

AJG:米多君、可乐定利于控制肝硬化难治性腹水

在肝硬化腹水患者中出现难治性腹水的几率约5% - 10%,此类患者死亡率极高。难治性腹水因内脏动脉血管舒张,交感神经系统(SNS)及肾素– 血管紧张素– 醛固酮系统(RAAS)过度活化所致。治疗难治性腹水的方案主要包括腹腔穿刺腹水引流术、肝移植、经颈静脉门体分流术等。目前血管加压治疗用于预防腹腔穿刺放腹水治疗后引起的体循环不良,如肝肾综合征等,发挥改善循环,保护肾功能的作用,并对顽固性腹水有一定治

Baidu
map
Baidu
map
Baidu
map